Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATFurniture, Fixtures and OtherLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShort-Term Debt repayments
Ratios

Plus Therapeutics (PSTV) Accumulated Depreciation & Amortization (2016 - 2025)

Plus Therapeutics has reported Accumulated Depreciation & Amortization over the past 15 years, most recently at $3.3 million for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 6.21% to $3.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.3 million through Dec 2025, up 6.21% year-over-year, with the annual reading at $3.3 million for FY2025, 6.21% up from the prior year.
  • Accumulated Depreciation & Amortization was $3.3 million for Q4 2025 at Plus Therapeutics, up from $3.1 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $3.3 million in Q4 2025 and troughed at $1.4 million in Q4 2021.
  • The 5-year median for Accumulated Depreciation & Amortization is $2.5 million (2023), against an average of $2.5 million.
  • Year-over-year, Accumulated Depreciation & Amortization grew 2.02% in 2021 and then surged 38.52% in 2022.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $1.4 million in 2021, then surged by 38.52% to $2.0 million in 2022, then increased by 29.39% to $2.5 million in 2023, then grew by 23.82% to $3.1 million in 2024, then grew by 6.21% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Accumulated Depreciation & Amortization are $3.3 million (Q4 2025), $3.1 million (Q4 2024), and $2.5 million (Q4 2023).